N24 Experience with Ustekinumab (STELARA®) in Paediatric inflammatory bowel disease (pIBD) – A case series
R. Buckingham*1, S. Sider1, L. Cococcioni1, A. ElZein1, S. Chadokufa1, N. Shah1, A. Ocholi1, O. Borrelli1, F. Kiparissi1
1Great Ormond Street Hospital, Gastroenterology, London, UK
Ustekinumab (UST) is a monoclonal antibody against IL 12/23 and is thought to drive inflammation in psoriasis and gastrointestinal inflammation. Two phase 2b studies have shown that UST induces and maintains clinical response in Crohn's disease (CD). Data of the effectiveness of UST in pIBD are lacking.
The aim of the study was to evaluate effectiveness and safety of UST as a treatment for pIBD after failure of anti-TNFa and Vedolizumab. Methods Retrospective study of demographic characteristics, medical history, dosage and schedule of UST administration, as well as data on pre and post ESR, calprotectin and PCDAI.
A total of 5 patients on UST were identified, age range 8–15 years, median 12 years, age at diagnosis 2–10 years, median 5 years, 3 males. Crohns
|Start date||Pre ESR||Post ESR||Pre Calprotectin||Post Calprotectin||Pre PCDAI||Post PCDAI|
|March 2018||No data||17||>1800||915||10|
Ustekinumab seems to be effective and safe treatment in pIBD patients with no reported adverse events. We suggest multi-centre prospective Paediatric studies to advance knowledge and improve patient outcomes.